United States Anatomic Pathology Market to Reach USD 31.1 Billion by 2030 | CAGR 8.3% | North America Leads with 35% Share | Key Players: Quest Diagnostics, Danaher, PHC Holdings, LabCorp, F. Hoffmann-La Roche, Agilent, Cardinal Health, Leica Biosystems,

Anatomic Pathology Market Overview:

The global anatomic pathology market reached US$ 16.7 billion in 2022 and is projected to grow to US$ 31.1 billion by 2030, registering a CAGR of 8.3% during the forecast period 2023-2030. The market is a critical component of modern healthcare, providing essential services for the diagnosis and characterization of diseases through the examination of tissues and cells. Anatomic pathology encompasses a broad range of laboratory tests and techniques used to detect and analyze conditions such as cancer, infectious diseases, and autoimmune disorders. These services are vital for accurate disease diagnosis, prognosis, and guiding treatment decisions, making them indispensable in clinical and research settings.

The growth of the anatomic pathology market is driven by multiple factors, including the rising prevalence of chronic diseases, the increasing demand for personalized medicine, and technological advancements in diagnostic tools and methodologies. Additionally, the aging global population and the continuous development of innovative anatomic pathology techniques, such as immunohistochemistry, molecular pathology, and digital pathology integration, are further fueling market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/anatomic-pathology-market?Juli

Recent Developments:

✅ October 2025: Roche Diagnostics launched an advanced digital anatomic pathology platform integrating AI-driven image analysis and cloud-based workflow management, enabling faster and more accurate cancer diagnostics.

✅ September 2025: Thermo Fisher Scientific introduced new automated tissue staining and imaging solutions for high-throughput anatomic pathology laboratories, improving diagnostic efficiency and consistency.

✅ August 2025: Agilent Technologies expanded its anatomic pathology product portfolio with novel molecular pathology assays for biomarker detection and precision medicine applications.

✅ July 2025: Leica Biosystems launched an upgraded digital slide scanning system with enhanced resolution and AI-assisted analysis, supporting remote diagnostics and telepathology initiatives.

✅ June 2025: Sysmex Corporation implemented a new integrated workflow solution combining histology, immunohistochemistry, and digital pathology to optimize laboratory operations and turnaround times.

✅ March 2025: Global anatomic pathology labs increasingly adopted AI-powered image analysis and digital pathology platforms to accelerate tissue examination, improve diagnostic accuracy, and support clinical research.

Mergers & Acquisitions:

✅ November 2025: Roche Diagnostics acquired a U.S.-based digital pathology and AI analytics startup to enhance its anatomic pathology platform with advanced image analysis and predictive diagnostics capabilities.

✅ September 2025: Thermo Fisher Scientific completed the acquisition of a European tissue imaging and slide scanning company to expand its high-throughput anatomic pathology solutions portfolio.

✅ July 2025: Leica Biosystems partnered with a cloud-based AI pathology startup to integrate remote diagnostic and telepathology capabilities into its digital slide scanning systems.

✅ June 2025: Agilent Technologies acquired a molecular pathology solutions provider to strengthen its biomarker detection and precision medicine offerings in anatomic pathology.

✅ March 2025: Sysmex Corporation acquired a workflow automation software firm to integrate AI-assisted digital pathology and laboratory information systems, enhancing operational efficiency for global pathology labs.

Key Players:
Quest Diagnostics Inc. | Danaher Corporation | PHC Holdings Corporation | Laboratory Corporation of America Holdings | F. Hoffmann-La Roche AG | Agilent Technologies Inc. | Cardinal Health Inc. | Sakura Finetek USA Inc. | NeoGenomics Laboratories Inc. | BioGenex

Key Highlights:

• Quest Diagnostics Inc. - 15.8% share: Leading provider of anatomic pathology services, offering clinical diagnostics, molecular testing, and AI-assisted pathology solutions.

• Danaher Corporation - 14.2% share: Supplies advanced laboratory instruments, automated tissue processing systems, and digital pathology solutions for hospitals and research labs.

• PHC Holdings Corporation - 11.6% share: Offers automated tissue processing, staining, and imaging systems for high-throughput pathology laboratories.

• Laboratory Corporation of America Holdings - 12.5% share: Provides comprehensive anatomic pathology services, including histology, immunohistochemistry, and molecular pathology testing.

• F. Hoffmann-La Roche AG - 10.8% share: Offers integrated digital pathology solutions, AI-powered image analysis, and biomarker detection platforms.

• Agilent Technologies Inc. - 9.7% share: Focuses on molecular and immunohistochemistry assays, tissue imaging, and precision medicine applications in pathology.

• Cardinal Health Inc. - 7.4% share: Supplies laboratory consumables, tissue reagents, and workflow solutions for anatomic pathology labs.

• Sakura Finetek USA Inc. - 6.5% share: Specializes in tissue processing, embedding, and slide staining equipment for pathology laboratories.

• NeoGenomics Laboratories Inc. - 6.0% share: Provides clinical and molecular anatomic pathology services, with a focus on oncology diagnostics and biomarker studies.

• BioGenex - 5.5% share: Offers immunohistochemistry and molecular pathology products, including automated staining and imaging systems for clinical labs and research institutions.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=anatomic-pathology-market?Juli

Market Segmentation:

➥ By Product & Service, the consumables segment leads with approximately 40% of the market, driven by high demand for reagents, staining kits, slides, and laboratory supplies required for routine tissue analysis. The instruments segment holds around 35%, fueled by adoption of automated tissue processors, imaging systems, and slide scanners, while services account for 25%, including histology, immunohistochemistry, molecular testing, and consulting for diagnostic and research applications.

➥ By Type, histopathology dominates with 55%, supported by widespread use in cancer diagnostics, tissue morphology analysis, and routine laboratory testing. Cytopathology accounts for 25%, while surgical pathology represents 20%, driven by growing demand for intraoperative diagnostics and precision medicine.

➥ By Technique, special staining leads with 30%, followed by immunohistochemistry (IHC) at 28%, which is widely used for biomarker detection and cancer diagnostics. Electron microscopy holds 15%, primarily for research and advanced diagnostics, and genetic testing accounts for 27%, growing rapidly due to personalized medicine and molecular pathology applications.

➥ By Application, disease diagnosis captures 60% of the market, as hospitals and diagnostic labs rely on anatomic pathology for accurate detection of cancers, infectious diseases, and autoimmune disorders. Drug discovery and development holds 40%, driven by pharmaceutical and biotechnology companies using tissue analysis, biomarker studies, and molecular profiling for clinical trials and precision medicine research.

➥ By End-User, hospitals lead with 45%, implementing anatomic pathology services in oncology and diagnostic departments. Research laboratories hold 30%, focusing on biomarker discovery, molecular analysis, and academic studies. Diagnostic laboratories account for 25%, leveraging automated workflows and AI-assisted pathology platforms for high-throughput testing and accurate disease diagnostics.

Regional Insights:

North America dominates the anatomic pathology market with a 35% share (USD 5.85 billion in 2022), driven by advanced healthcare infrastructure, high adoption of automated instruments, AI-assisted image analysis, and strong regulatory support. The U.S. leads the region due to widespread deployment of digital pathology, immunohistochemistry, and molecular diagnostics in hospitals, research laboratories, and diagnostic centers.

Europe holds a 28% share (USD 4.68 billion in 2022), supported by government initiatives promoting healthcare modernization, precision medicine, and digital pathology adoption. Key markets such as Germany, France, and the UK are investing in automated tissue processing, advanced staining techniques, and AI-enabled pathology platforms, accelerating market growth.

Asia-Pacific is the fastest-growing region, accounting for 22% (USD 3.67 billion in 2022), with a projected CAGR of over 9% during 2023-2030. Growth is driven by rising healthcare expenditure, increasing prevalence of chronic diseases and cancer, and adoption of digital and molecular pathology platforms in countries such as China, Japan, and India.

Latin America, Middle East & Africa (LAMEA) contribute 15% (USD 2.51 billion in 2022), supported by expanding healthcare infrastructure, growing awareness of anatomic pathology, and investments in diagnostic laboratories and research centers. Key markets include Brazil, Mexico, South Africa, and the UAE, where advanced tissue diagnostics and molecular testing are increasingly being implemented.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/anatomic-pathology-market?Juli

Market Dynamics:

Drivers
The market growth is primarily driven by the increasing prevalence of chronic diseases, cancer, and infectious disorders, which are fueling demand for accurate tissue-based diagnostics. Advancements in digital pathology, AI-assisted image analysis, immunohistochemistry, and molecular testing are enhancing diagnostic speed, accuracy, and efficiency. Rising adoption of personalized medicine and precision oncology is also accelerating demand, as anatomic pathology plays a critical role in biomarker identification, treatment selection, and prognostic evaluation. Furthermore, expansion of healthcare infrastructure, growing investments in research laboratories, and regulatory approvals for digital pathology systems are supporting market growth globally.

Restraints
High costs associated with advanced anatomic pathology instruments, automated workflow systems, and AI-enabled digital platforms can limit adoption, especially in emerging and price-sensitive markets. Integration complexity with existing laboratory workflows, lack of standardized protocols, and data privacy or regulatory compliance challenges may slow implementation. Additionally, limited technical expertise and resistance to adopting new technologies among traditional pathology laboratories can hinder widespread deployment.

Opportunities
Significant opportunities exist in digital pathology integration, AI-driven image analysis, cloud-based workflow platforms, and molecular pathology solutions for both clinical and research applications. Emerging economies in Asia-Pacific, Latin America, and the Middle East are expected to witness strong growth due to increasing healthcare investment, rising disease prevalence, and adoption of advanced laboratory solutions. Collaboration between pathology solution providers and hospitals, research institutes, and pharmaceutical companies can further expand market reach. Adoption of telepathology, remote diagnostics, and AI-assisted biomarker studies presents additional avenues for growth.

Trends
The market is witnessing a shift toward AI- and cloud-enabled digital pathology platforms that facilitate remote consultations, telepathology, and high-throughput image analysis. There is growing emphasis on workflow automation, integration of molecular diagnostics, and predictive analytics to improve laboratory efficiency and accuracy. Personalized medicine, oncology-focused diagnostics, and data-driven research are increasingly driving adoption, with a focus on reducing diagnostic errors, enhancing operational efficiency, and supporting advanced clinical and research applications.

Key Developments:

✅ April 17, 2023: Xyall and Indica Labs entered into a global strategic partnership to bridge the gap between histology and molecular pathology. This collaboration integrates Xyall's automated Tissector tissue dissection solutions with Indica Labs' HALO AP anatomic pathology image management and workflow software, enabling primary diagnosis, remote slide review, case sign-out, and enhanced workflow efficiency.

✅ April 10, 2023: Versant Diagnostics, an independent physician services company, announced a joint collaboration with In-Office Pathology, LLC (IOP) to expand access to pathologists and build in-office laboratories. Versant Diagnostics will provide anatomic pathology services to IOP's network, while IOP will establish labs at select Versant specialty clinics and physician practices, enhancing local pathology capabilities.

✅ September 23, 2022: Epredia, a global leader in precision cancer diagnostics, announced that its parent company PHC Holdings Corporation acquired Microm Microtech France (MM France) and Laurypath, anatomical pathology equipment suppliers. This acquisition strengthens Epredia's presence in Europe and expands its portfolio of pathology solutions for research and clinical applications.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.